The Effects of a Single Evening Dose of 3 Mg Eszopiclone on Next Day Driving Ability and Psychomotor/Memory Function in Patients With Primary Insomnia Compared to Placebo.
Information source: Sepracor, Inc.
Information obtained from ClinicalTrials.gov on October 19, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Primary Insomnia
Intervention: Eszopiclone (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: Sepracor, Inc.
Summary
To assess next day driving ability and psychomotor/memory function following a single night time dose of eszopiclone.
Clinical Details
Study design: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety Study
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Male and female patients with primary insomnia must be in good general health. Patients must also possess a full current driving license (for at least one year), and be a regular car driver.
Exclusion Criteria:
-
Locations and Contacts
Additional Information
Last updated: August 23, 2006
|
